Lima Catarina Tenório de, Araújo Paulo Sérgio Ramos de, Teixeira Heberton Medeiros de, Santos Josemir Belo Dos, Silveira Vera Magalhães da
Commission and Hospital Infection Control Service of the Hospital Barão de Lucena - Recife (PE), Brazil.
Department of Tropical Medicine - Universidade Federal de Pernambuco (UFPE) - Recife (PE), Brazil.
An Bras Dermatol. 2017 Mar-Apr;92(2):172-176. doi: 10.1590/abd1806-4841.20175377.
: Kaposi's sarcoma continues to be the most common human immunodeficiency virus - associated neoplasm with considerable morbidity and mortality.
: To describe the clinical and laboratory characteristics, initial staging, and outcomes of aids patients with Kaposi's sarcoma at an university hospital of Recife, Pernambuco.
: This is a descriptive study with analytic character, retrospective, of a case series between 2004 and 2014.
: Of the 22 patients included in the study, 20 were aged <40 years (72.7%). The majority had CD4+ T lymphocyte counts of <200 cells/mm3 (77.3%) and human immunodeficiency virus loads of <100,000 copies/mL (78.9%). Lesions were most commonly observed on the skin (90%), and internal organs were affected in 11 of the 22 patients. Only 7 (31.8%) of the 22 patients were undergoing antiretroviral therapy (ART) at the time of Kaposis sarcoma diagnosis, and the initial disease staging classification was high risk (Aids Clinical Trials Group Oncology Committee) in 19 of the 22 patients (86.4%). Regarding Kaposi's sarcoma treatment, 17 of 22 patients (77.3%) underwent systemic chemotherapy + ART and 5 were treated exclusively with ART. Eight of the 22 patients died (36.5%); of these, 87.5% had died within one year of Kaposi's sarcoma diagnosis.
: Without a control group, this study cannot be used to generate hypotheses.
: Despite the association between aids and late Kaposi's sarcoma diagnosis in the study population, including an unfavorable risk at the time of staging, a lower mortality rate was observed relative to other studies; this might be related to access to a specialized health service.
卡波西肉瘤仍然是最常见的与人类免疫缺陷病毒相关的肿瘤,具有相当高的发病率和死亡率。
描述累西腓市、伯南布哥州一家大学医院中艾滋病合并卡波西肉瘤患者的临床和实验室特征、初始分期及预后。
这是一项2004年至2014年间病例系列的具有分析性质的回顾性描述性研究。
纳入研究的22例患者中,20例年龄小于40岁(72.7%)。大多数患者的CD4 + T淋巴细胞计数小于200个细胞/mm³(77.3%),人类免疫缺陷病毒载量小于100,000拷贝/mL(78.9%)。病变最常出现在皮肤(90%),22例患者中有11例累及内脏器官。22例患者中仅7例(31.8%)在卡波西肉瘤诊断时正在接受抗逆转录病毒治疗(ART),22例患者中有19例(86.4%)的初始疾病分期分类为高风险(艾滋病临床试验组肿瘤学委员会)。关于卡波西肉瘤的治疗,22例患者中有17例(77.3%)接受了全身化疗 + ART,5例仅接受ART治疗。22例患者中有8例死亡(36.5%);其中,87.5%在卡波西肉瘤诊断后一年内死亡。
由于没有对照组,本研究不能用于提出假设。
尽管在研究人群中艾滋病与卡波西肉瘤的晚期诊断相关,包括分期时风险不利,但相对于其他研究观察到较低的死亡率;这可能与获得专业医疗服务有关。